Compare · AMGN vs DNA
AMGN vs DNA
Side-by-side comparison of Amgen Inc. (AMGN) and Ginkgo Bioworks Holdings Inc. (DNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and DNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $226.05B, about 335.9x DNA ($673.0M).
- Over the past year, AMGN is up 54.5% and DNA is down 9.5% - AMGN leads by 64.1 points.
- AMGN has been more active in the news (8 items in the past 4 weeks vs 5 for DNA).
- AMGN has more recent analyst coverage (25 ratings vs 18 for DNA).
- Company
- Amgen Inc.
- Ginkgo Bioworks Holdings Inc.
- Price
- $423.54+1.23%
- $11.97+14.33%
- Market cap
- $226.05B
- $673.0M
- 1M return
- -2.06%
- +71.61%
- 1Y return
- +54.54%
- -9.52%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NYSE
- IPO
- 1983
- 2021
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 18
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Latest AMGN
- FDA Approval for RIABNI issued to AMGEN INC
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
- FDA Approval for IMDELLTRA issued to AMGEN INC
- FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
- AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Amgen downgraded by BMO Capital Markets with a new price target
- New insider Dittrich Thomas J.W. claimed ownership of 16,860 shares (SEC Form 3)
- AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
Latest DNA
- Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
- Director Henry Christian O sold $35,405 worth of shares (5,000 units at $7.08), decreasing direct ownership by 21% to 19,310 units (SEC Form 4)
- Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
- SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
- Officer Coen Steven P. converted options into 743 shares and sold $2,302 worth of shares (330 units at $6.98), increasing direct ownership by 0.80% to 51,851 units (SEC Form 4) (tax liability)
- Ginkgo Bioworks downgraded by TD Cowen with a new price target
- SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4 filed by Large owner Canton Barry